MiMedx Group, Inc (NASDAQ:MDXG) Short Interest Update

MiMedx Group, Inc (NASDAQ:MDXG) saw a large increase in short interest during the month of March. As of March 31st, there was short interest totaling 7,668,857 shares, an increase of 24.1% from the March 15th total of 6,179,889 shares. Based on an average daily volume of 1,217,031 shares, the short-interest ratio is presently 6.3 days. Currently, 5.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. World Investment Advisors purchased a new position in shares of MiMedx Group in the 4th quarter valued at $173,000. Virtu Financial LLC purchased a new position in shares of MiMedx Group in the 4th quarter valued at $78,000. Invesco Ltd. grew its position in shares of MiMedx Group by 5.9% in the 4th quarter. Invesco Ltd. now owns 84,824 shares of the company’s stock valued at $574,000 after buying an additional 4,708 shares during the last quarter. Corient Private Wealth LLC grew its position in shares of MiMedx Group by 26.0% in the 4th quarter. Corient Private Wealth LLC now owns 46,658 shares of the company’s stock valued at $316,000 after buying an additional 9,614 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV grew its position in shares of MiMedx Group by 33.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,786 shares of the company’s stock valued at $141,000 after buying an additional 5,236 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Stock Down 12.2%

Shares of NASDAQ MDXG traded down $0.48 during mid-day trading on Thursday, reaching $3.41. The company had a trading volume of 3,229,486 shares, compared to its average volume of 1,084,133. The company has a current ratio of 4.32, a quick ratio of 3.92 and a debt-to-equity ratio of 0.06. The firm has a 50 day simple moving average of $4.52 and a two-hundred day simple moving average of $5.90. The stock has a market cap of $505.88 million, a P/E ratio of 10.64 and a beta of 1.65. MiMedx Group has a 52-week low of $3.31 and a 52-week high of $7.99.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Wednesday, February 25th. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $118.10 million for the quarter, compared to the consensus estimate of $106.78 million. MiMedx Group had a net margin of 11.60% and a return on equity of 29.37%. Sell-side analysts predict that MiMedx Group will post 0.3 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on MDXG. Wall Street Zen downgraded shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Mizuho dropped their price objective on shares of MiMedx Group from $12.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 17th. Cantor Fitzgerald dropped their price objective on shares of MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. UBS Group set a $10.00 price objective on shares of MiMedx Group in a research report on Monday, February 23rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of MiMedx Group in a research report on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, MiMedx Group currently has an average rating of “Moderate Buy” and a consensus target price of $9.60.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.